Stockscreener 앱 받기
8.69
2.69%
-0.24
시간 외 거래:
8.84
0.15
+1.73%
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics N.V. (NASDAQ:IMTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
James Nelson Pepin Net Worth (2026) - GuruFocus
Immatics (NASDAQ:IMTX) Shares Down 8%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Immatics Announces Second Quarter 2026 Financial Results and Business Update - Sahm
Immatics (IMTX) awards counsel Nelson 225K share package - Stock Titan
Immatics Releases Q2 2026 Financial Results - AlphaStreet
Immatics Q2 revenue rises to $10.4 million - grafa.com
Immatics earnings on deck as analysts eye revenue trajectory - Investing.com
Immatics Q2 Results: EPS misses estimate, sales up 93% YoY - scanx.trade
IMTX Looks 176.9% Overvalued on GF Value™ - GuruFocus
Immatics (NASDAQ:IMTX) Issues Earnings Results - MarketBeat
Immatics (IMTX) Slides 2.01% as Shares Approach Key $8.79 Support LevelQuality Factor - Vinanet
Immatics Posts Interim Q2 2026 Results and Updates Investor Materials - TipRanks
Immatics' Q2 Net Loss Narrows as Revenue Rises - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Revenue 9.1M Euros, vs. FactSet Est of 10.4M Euros - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q2 Net Loss 0.46 Euros a Share, vs. FactSet Est of 0.45 Euros Loss - marketscreener.com
Immatics reports Q2 EPS (46c), consensus (48c) - TipRanks
Immatics: Q2 Earnings Snapshot - marketscreener.com
Immatics (NASDAQ: IMTX) posts €120m loss funding Phase 3 melanoma push - Stock Titan
Immatics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Press Release: Immatics Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentEPS Surprise History - vinanet.vn
Immatics (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Preclinical and Clinical InvestmentConsensus Beat Rate - dars.gov.et
Immatics (IMTX): Baker Bros. group reports 9.5M-share, 7% ownership stake - Stock Titan
Immatics NV (IMTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immatics N.V. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Immatics N.V. (IMTX) Stock Analysis: Unveiling An 89.67% Potential Upside For Investors - DirectorsTalk Interviews
IMTX Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D-Driven BurnDividend Cut Risk - vinanet.vn
How Immatics N.v. (IMTX) Affects Rotational Strategy Timing - Stock Traders Daily
Immatics (IMTX): Will Anzu-cel Take The PRAME Crown In Advanced Melanoma? - RTTNews
Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Immatics (IMTX) Slips 5.9% to $8.66 as Biotech Selling Pressure IntensifiesIron Condor Alert - Vinanet
Immatics N.V. (IMTX) Stock Analysis: Exploring a 105% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
IMTX|Immatics NV|Price:9.425|Chg%:-0.165 - TradingKey
Immatics (NASDAQ:IMTX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Immatics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-than-Expected Loss Amid Continued Clinical ProgressFinancial Data - dars.gov.et
Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immatics Market Sentiment - Benzinga
Immatics NV (IMTX) Cash Flow - TradingKey
Immatics N.V. Revenue Breakdown – NASDAQ:IMTX - TradingView
IMTX|Immatics NV|Price:9.080|Chg%:-0.210 - TradingKey
Immatics NV (IMTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immatics NV (IMTX) Income Statement - TradingKey
Immatics N.V. (IMTX) Stock Analysis: A Deep Dive Into Its 103% Potential Upside - DirectorsTalk Interviews
Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immatics NV : Leerink Partners Assumes Covera - Moomoo
Immatics stock trades steady as pipeline and cash position frame biotech outlook - Ad-hoc-news.de
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflected in Wider Loss, Yet Stock Rises on Pipeline ProgressInterim Report - dars.gov.et
Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026 - Bitget
Immatics N.V. (IMTX) Stock: Cancer Treatment Pipeline Gains Momentum With Cell Therapy and Bispecific Programs - parameter.io
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 - Investing News Network
MRNA Advances Cancer Pipeline With New Immunotherapy Study - TradingView
Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline - Quiver Quantitative
Immatics’ three ESMO presentations span melanoma and solid tumors - Stock Titan
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflects Clinical-Stage R&D InvestmentEarnings Growth Analysis - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Amid Continued Pipeline ProgressPre-Announcement Alert - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances PipelineEBITDA Margin Trends - dars.gov.et
Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Biotech Navigates Clinical Pipeline CostsEstimate Dispersion - dars.gov.et
(IMTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immatics (IMTX) Dips 2.8% as Biotech Stock Tests Key Support Near $9.20Buffered ETF - dars.gov.et
Immatics (IMTX) Slides 3.11% Amid Biotech Sector Pressure – Support at $9.17 in FocusRounding Bottom - dars.gov.et
Immatics (IMTX) Holds Near Support as Slight Dip Signals Cautious TradingGap Down Bounce Plays - dars.gov.et
0.00%
3.22%
자본화:
|
볼륨(24시간):